問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

葉雲凱YEH, YUN-KAI
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

32Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉雲凱

List

39Cases

2021-09-01 - 2023-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2021-06-14 - 2022-05-13

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-09-01 - 2028-12-31

Phase III

Active
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab) / JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2020-11-01 - 2026-06-30

Phase III

Active
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372(Amivantamab)

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-11-01 - 2026-06-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab)JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting2Sites

Terminated1Sites

2020-08-21 - 2024-03-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-08-21 - 2029-05-31

Phase III

Active
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer

  • Condition/Disease

    Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer

  • Test Drug

    Osimertinib (AZD9291/TAGRISSOR/泰格莎)

Participate Sites
7Sites

Recruiting7Sites

2019-04-01 - 2025-12-31

Phase II

Active
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)

  • Condition/Disease

    Locally Advanced or Metastatic Non Small Cell Lung Cancer

  • Test Drug

    TAGRISSO and Savolitinib

Participate Sites
10Sites

Recruiting10Sites

2020-11-01 - 2027-06-30

Phase I

Active
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)

  • Condition/Disease

    Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    ENHERTUR

Participate Sites
8Sites

Recruiting8Sites

2022-09-15 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB